[go: up one dir, main page]

WO2009021991A9 - Verwendung von r(+)-alpha-liponsäure bei kryptogener neuropathie - Google Patents

Verwendung von r(+)-alpha-liponsäure bei kryptogener neuropathie Download PDF

Info

Publication number
WO2009021991A9
WO2009021991A9 PCT/EP2008/060688 EP2008060688W WO2009021991A9 WO 2009021991 A9 WO2009021991 A9 WO 2009021991A9 EP 2008060688 W EP2008060688 W EP 2008060688W WO 2009021991 A9 WO2009021991 A9 WO 2009021991A9
Authority
WO
WIPO (PCT)
Prior art keywords
cryptogenic
neuropathy
alpha
lipoic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/060688
Other languages
English (en)
French (fr)
Other versions
WO2009021991A1 (de
Inventor
Klaus Wessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encrypta GmbH
Original Assignee
Encrypta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encrypta GmbH filed Critical Encrypta GmbH
Priority to US12/673,654 priority Critical patent/US8722013B2/en
Publication of WO2009021991A1 publication Critical patent/WO2009021991A1/de
Anticipated expiration legal-status Critical
Publication of WO2009021991A9 publication Critical patent/WO2009021991A9/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von R(+)-alpha-Liponsäure ((R)-5-(1,2-Dithiolan-3-yl)valeriansäure) und/oder eines physiologisch annehmbaren Derivats dieser Verbindung bei kryptogener Neuropathie.
PCT/EP2008/060688 2007-08-16 2008-08-14 Verwendung von r(+)-alpha-liponsäure bei kryptogener neuropathie Ceased WO2009021991A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/673,654 US8722013B2 (en) 2007-08-16 2008-08-14 Use of R(+)-alpha-lipoic acid for cryptogenic neuropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007038849A DE102007038849A1 (de) 2007-08-16 2007-08-16 Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
DE102007038849.9 2007-08-16

Publications (2)

Publication Number Publication Date
WO2009021991A1 WO2009021991A1 (de) 2009-02-19
WO2009021991A9 true WO2009021991A9 (de) 2010-04-29

Family

ID=39831953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/060688 Ceased WO2009021991A1 (de) 2007-08-16 2008-08-14 Verwendung von r(+)-alpha-liponsäure bei kryptogener neuropathie

Country Status (3)

Country Link
US (1) US8722013B2 (de)
DE (1) DE102007038849A1 (de)
WO (1) WO2009021991A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157405A1 (en) * 2010-12-19 2012-06-21 White Iii John B Methods and Compositions for the Treatment of "Burning Feet Syndrome"
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2112874T3 (es) 1991-07-05 1998-04-16 Asta Medica Ag Utilizacion de acidos carboxilicos con contenido en azufre para combatir trastornos de excitacion de origen patofisiologico.
DE4327462A1 (de) 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4343592C2 (de) 1993-12-21 1998-04-16 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems
DE4343593C2 (de) 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
EP0855396A1 (de) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Metabolite von Thioctsäure und deren Verwendung
AU728488B2 (en) 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
WO1999006040A1 (en) 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
WO1999013861A1 (en) 1997-09-12 1999-03-25 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
GB9802155D0 (en) 1998-02-03 1998-04-01 Taylor Mark Sleeping parent
DE19806354B4 (de) 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
JP2002530396A (ja) 1998-11-25 2002-09-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム スカベンジャー化合物
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
DE19938621A1 (de) 1999-08-14 2001-02-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von lösemittelfreier alpha-Liponsäure
DE60108089T2 (de) 2000-03-16 2006-03-02 Societe De Conseils De Recherches Et D`Applications Scientifiques (S.C.R.A.S.) Heterozyklische oder Benzol-Derivate von Liponsäure, deren Herstellung und Ederen Verwendung als Heilmittel
US6387945B2 (en) 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
US7700080B2 (en) 2001-03-19 2010-04-20 Senju Pharmaceutical Co., Ltd. Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives
AU2002254546A1 (en) 2002-04-03 2003-10-20 Mitchell A. Avery Lipoic acid analogs useful as provitamins and antioxidants
DE10223882A1 (de) 2002-05-29 2003-12-18 Degussa Fliessfähige, pulverförmige Liponsäure(-Derivate) enthaltende Zusammensetzung
ITMI20061024A1 (it) 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
US9755433B2 (en) 2013-11-20 2017-09-05 Abb Schweiz Ag Hybrid alternating current (AC)/direct current (DC) distribution for multiple-floor buildings

Also Published As

Publication number Publication date
US20100310538A1 (en) 2010-12-09
DE102007038849A1 (de) 2009-02-19
US8722013B2 (en) 2014-05-13
WO2009021991A1 (de) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009156462A3 (en) Organic compounds
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009043889A3 (en) Oxadiazole derivatives
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
WO2009111653A3 (en) Antiviral therapeutic agents
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007061923A3 (en) Glucokinase activators
WO2007028135A3 (en) Imidazopyridine compounds
UA94833C2 (en) Substituted bicyclolactams
WO2007093627A3 (de) Biozide zusammensetzung
WO2009039951A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2008017346A3 (de) Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2009022311A3 (en) 1,2-diamido-ethylene derivatives as orexin antagonists
WO2010018549A3 (en) Therapeutic compositions containing macitentan
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2010043717A3 (en) Pharmaceutical topical compositions
WO2009124962A3 (en) Sulfonamides
WO2009055289A3 (en) Therapeutic substituted lactams
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2009103813A3 (de) Fungizide zusammensetzungen mit 3'-brom-2,3,4,6'-tetramethoxy-2'-6-dimethylbenzophenon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787223

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12673654

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08787223

Country of ref document: EP

Kind code of ref document: A1